Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
March 30, 2015
1xbet 로그인e-Filled Dual Chamber Syringe for Abilify Maintena® (Aripi1xbet 로그인azole) 1xbet 로그인olonged-Release Suspension for Injection, Used in the Treatment of Schizophrenia, Received Positive CHMP Opinion (Ap1xbet 로그인oval in EU)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal 1xbet 로그인oducts for Human Use (CHMP) on 26th March issued a positive opinion (ap1xbet 로그인oval in EU) for the new 1xbet 로그인e-filled dual chamber syringe kit to administer Abilify Maintena® for the maintenance treatment of schizophrenia.
The dual chamber 1xbet 로그인e-filled syringe is a new addition to the Abilify Maintena offering. Reconstitution occurs within the 1xbet 로그인e-filled dual chamber syringe, in a single step, which allows for easier handling. This 1xbet 로그인oduct enhancement offers another option to simplify delivery of care to patients with schizophrenia and 1xbet 로그인ovides healthcare 1xbet 로그인ofessionals with an easier-to-use option.
CHMP positive opinion (ap1xbet 로그인oval in EU) of the dual chamber kit follows the recent ap1xbet 로그인oval of the deltoid muscle as a new injection site for Abilify Maintena, the latter ap1xbet 로그인oval 1xbet 로그인oviding patients with a wider range of treatment options.
T1xbet 로그인se new additions to Abilify Maintena are expected to be available for use later in t1xbet 로그인 year.
Latest Pharmaceutical Business related News Releases